CY1971A - Pyrazolopyrimidinone antianginal agents - Google Patents

Pyrazolopyrimidinone antianginal agents

Info

Publication number
CY1971A
CY1971A CY197197A CY197197A CY1971A CY 1971 A CY1971 A CY 1971A CY 197197 A CY197197 A CY 197197A CY 197197 A CY197197 A CY 197197A CY 1971 A CY1971 A CY 1971A
Authority
CY
Cyprus
Prior art keywords
alkyl
cycloalkyl
alkoxy
perfluoroalkyl
conr
Prior art date
Application number
CY197197A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10677918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CY1971A publication Critical patent/CY1971A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00—Program-control systems
    • G05B2219/30—Nc systems
    • G05B2219/36—Nc in input of data, input key till input tape
    • G05B2219/36395—Load local computer program from host, data transfer ram to rom, BTR

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CY197197A 1990-06-20 1997-09-05 Pyrazolopyrimidinone antianginal agents CY1971A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909013750A GB9013750D0 (en) 1990-06-20 1990-06-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
CY1971A true CY1971A (en) 1997-09-05

Family

ID=10677918

Family Applications (2)

Application Number Title Priority Date Filing Date
CY197197A CY1971A (en) 1990-06-20 1997-09-05 Pyrazolopyrimidinone antianginal agents
CY1999011C CY99011I2 (en) 1990-06-20 1999-05-24 Pyrazolopyrimidinone antianginal agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY1999011C CY99011I2 (en) 1990-06-20 1999-05-24 Pyrazolopyrimidinone antianginal agents

Country Status (31)

Country Link
EP (1) EP0463756B1 (cs)
JP (1) JPH07121945B2 (cs)
KR (1) KR940006628B1 (cs)
CN (1) CN1028758C (cs)
AT (1) ATE121403T1 (cs)
AU (1) AU626757B2 (cs)
BR (1) BR9102560A (cs)
CA (1) CA2044748C (cs)
CY (2) CY1971A (cs)
CZ (1) CZ279289B6 (cs)
DE (2) DE19975015I2 (cs)
DK (1) DK0463756T3 (cs)
EG (1) EG19651A (cs)
ES (1) ES2071919T4 (cs)
FI (1) FI95132C (cs)
GB (1) GB9013750D0 (cs)
HK (1) HK219496A (cs)
HU (1) HU218945B (cs)
IE (1) IE66040B1 (cs)
IL (1) IL98482A (cs)
LU (1) LU90360I2 (cs)
MY (1) MY107176A (cs)
NL (1) NL990005I2 (cs)
NO (2) NO178029C (cs)
NZ (1) NZ238586A (cs)
PL (1) PL166490B1 (cs)
PT (1) PT98011B (cs)
RU (2) RU2114114C1 (cs)
TW (1) TW222633B (cs)
YU (1) YU47962B (cs)
ZA (1) ZA914707B (cs)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0193801A (ja) * 1987-10-05 1989-04-12 Fanuc Ltd コントロールプログラムのローディング装置
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE4211239C2 (de) * 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
JP3726306B2 (ja) * 1994-04-27 2005-12-14 日産化学工業株式会社 ピラゾールカルボン酸誘導体および植物病害防除剤
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
CZ280697A3 (cs) * 1995-03-10 1998-04-15 Sanofi Pharmaceuticals, Inc. 6 aryl-pyrazolo(3,4-d)pyrimidin-4-ony a kompozice je obsahující, a způsob jejich použití
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
HUP9901478A3 (en) * 1996-05-10 1999-11-29 Icos Corp Bothell Carboline derivatives, their use, production thereof and medicaments containing the same
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
HRP970348A2 (en) * 1996-07-17 1998-04-30 Bayer Ag New nitropyrazole esters, process for their preparation and their use for the preparation of nytropyrazolamides
CA2270118A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
DE19701277A1 (de) * 1997-01-16 1998-07-23 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
EA002057B1 (ru) 1997-04-25 2001-12-24 Пфайзер Инк. ПИРАЗОЛОПИРИМИДИНОНЫ, КОТОРЫЕ ИНГИБИРУЮТ ЦИКЛИЧЕСКИЙ ГУАНОЗИН-3',5'-МОНОФОСФАТ-ФОСФОДИЭСТЕРАЗУ ТИПА 5 (cGMP PDE5), ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОГО РАССТРОЙСТВА
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
SI1049695T1 (en) 1997-11-12 2002-06-30 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
PT1073658E (pt) * 1998-04-20 2003-12-31 Pfizer Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19829616A1 (de) 1998-07-02 2000-01-05 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
ES2205945T3 (es) * 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
RU2220145C2 (ru) * 1998-11-11 2003-12-27 Донг А Фарм. Ко., Лтд. Производные пиразолопиримидинона для лечения импотенции и способ их получения
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
EP1002798A1 (en) * 1998-11-20 2000-05-24 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
AU3347300A (en) * 1999-01-28 2000-08-18 Sepracor, Inc. Desmethylsildenafil compositions and methods
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
WO2000051614A1 (en) * 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
IL130968A (en) 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
EP1077214A1 (en) * 1999-08-16 2001-02-21 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a pyrazolopyrimidinone derivative
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20020038941A (ko) * 1999-10-11 2002-05-24 디. 제이. 우드, 스피겔 알렌 제이 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
BR0017043A (pt) 1999-12-24 2003-01-07 Bayer Ag Imidazo[1,3,5]triazinonas e sua aplicação
EP1252165A1 (de) 1999-12-24 2002-10-30 Bayer Aktiengesellschaft Isoxazolopyrimidinone und ihre verwendung
US6683081B2 (en) 1999-12-24 2004-01-27 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
AU2000254308A1 (en) * 2000-05-17 2001-11-26 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
DE60107248T2 (de) * 2000-06-22 2005-12-01 Pfizer Inc. Neues verfahren zur herstellung von pyrazolopyrimidonen
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
KR100377782B1 (ko) * 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
EP1176147A1 (en) * 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
CN1446084A (zh) * 2000-08-11 2003-10-01 辉瑞大药厂 胰岛素抗性综合症的治疗
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
AU2000267375A1 (en) * 2000-08-23 2002-03-04 Lg Life Sciences Ltd. Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
RU2003106192A (ru) * 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Способ лечения аллергий
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
JP4450365B2 (ja) 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
DE10155018A1 (de) * 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
JP2005509038A (ja) 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
BR0207215A (pt) 2001-12-13 2004-02-10 Daiichi Suntory Pharma Co Ltd Derivados de pirazolopiriminona tendo ação de inibição de pde7
IL162602A0 (en) 2001-12-20 2005-11-20 Applied Research Systems Pyrrolidine derivatives as prostaglandin modulators
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
KR100435514B1 (ko) * 2002-03-22 2004-06-10 한미약품 주식회사 실데나필 젖산염의 속효제형
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20050004195A (ko) * 2002-05-23 2005-01-12 화이자 인코포레이티드 신규 조합 제제
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1572173B1 (en) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
CN1791429A (zh) 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
PT1633364E (pt) * 2004-01-05 2008-05-29 Teva Pharma Métodos para a produção de sildenafil base e sal citrato de sildenafil
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
UA84688C2 (uk) * 2005-04-15 2008-11-25 Виктор Павлович Кутняк Засіб для лікування еректильної дисфункції
DK2366393T3 (da) 2005-04-19 2013-10-21 Takeda Gmbh Roflumilast til behandlingen af pulmonal hypertension
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EP2508523B2 (en) 2007-10-23 2019-04-17 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2374460A4 (en) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
ES2775902T3 (es) 2009-11-27 2020-07-28 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo
CN101870699B (zh) * 2010-04-06 2013-11-20 漆又毛 苯磺酰基哌嗪衍生物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
KR102034748B1 (ko) 2011-03-01 2019-10-21 시너지 파마슈티컬즈 인코포레이티드 구아닐레이트 사이클라제 c 작용제의 제조 방법
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
SG11201402111QA (en) 2011-11-25 2014-08-28 Bayer Pharma AG Method for producing substituted 5-fluoro-1h-pyrazolopyridines
BR112015003380A2 (pt) * 2012-08-23 2017-07-04 Mitsubishi Tanabe Pharma Corp composto de pirazolopirimidina
EA201500852A1 (ru) 2013-02-21 2016-02-29 Адверио Фарма Гмбх Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治療胃腸道病症的組成物
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN103755709B (zh) * 2014-01-15 2016-05-25 广东药学院 西地那非衍生物的微波辅助制备方法
CN105017255A (zh) * 2014-04-25 2015-11-04 浙江泰康药业集团有限公司 西地那非制备工艺
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN107880047A (zh) * 2015-07-23 2018-04-06 青岛华之草医药科技有限公司 一种枸橼酸西地那非化合物
LT3377495T (lt) 2015-11-16 2022-05-25 Topadur Pharma Ag 2-fenil-3,4-dihidropirolo[2,1-f] [1,2,4]triazinono dariniai kaip fosfodiesterazės inhibitoriai ir jų naudojimas
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
US11969462B2 (en) 2017-06-21 2024-04-30 Transgene Personalized vaccine
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
AU2019319004B2 (en) 2018-08-06 2025-04-24 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
IL282618B2 (en) 2018-11-28 2025-05-01 Topadur Pharma Ag Novel dual-action soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses
MX2021007860A (es) 2018-12-28 2021-10-26 Transgene Poxvirux deficiente en m2.
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN118878542A (zh) * 2024-07-16 2024-11-01 西安市食品药品检验所 一种豪莫西地那非衍生物及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators

Also Published As

Publication number Publication date
DE69108991D1 (de) 1995-05-24
RU2047617C1 (ru) 1995-11-10
DK0463756T3 (da) 1995-09-25
PL290721A1 (en) 1992-03-23
FI95132C (fi) 1995-12-27
HK219496A (en) 1997-01-03
NL990005I2 (nl) 1999-06-01
FI95132B (fi) 1995-09-15
IE66040B1 (en) 1995-12-13
NL990005I1 (nl) 1999-05-03
EP0463756B1 (en) 1995-04-19
DE19975015I2 (de) 2006-03-16
HUT61312A (en) 1992-12-28
NO178029C (no) 1996-01-10
TW222633B (cs) 1994-04-21
NO1999004I2 (no) 2012-06-04
YU47962B (sh) 1996-07-24
KR940006628B1 (ko) 1994-07-23
IL98482A0 (en) 1992-07-15
EP0463756A1 (en) 1992-01-02
CZ279289B6 (cs) 1995-04-12
PL166490B1 (pl) 1995-05-31
EG19651A (en) 1995-10-31
RU2114114C1 (ru) 1998-06-27
FI913017A7 (fi) 1991-12-21
CS187691A3 (en) 1992-04-15
CA2044748A1 (en) 1991-12-21
LU90360I2 (fr) 1999-05-03
JPH07121945B2 (ja) 1995-12-25
ATE121403T1 (de) 1995-05-15
FI913017A0 (fi) 1991-06-19
NZ238586A (en) 1993-08-26
PT98011A (pt) 1992-03-31
CN1028758C (zh) 1995-06-07
MY107176A (en) 1995-09-30
IL98482A (en) 1995-11-27
AU626757B2 (en) 1992-08-06
HU912061D0 (en) 1991-12-30
HU218945B (hu) 2001-01-29
ES2071919T4 (es) 2011-08-30
YU108791A (sh) 1994-01-20
CY99011I2 (en) 2010-07-28
BR9102560A (pt) 1992-01-21
NO912366D0 (no) 1991-06-18
JPH0641133A (ja) 1994-02-15
NO912366L (no) 1991-12-23
PT98011B (pt) 1997-04-30
AU7915591A (en) 1992-03-19
KR920000761A (ko) 1992-01-29
DE69108991T2 (de) 1995-08-31
NO178029B (no) 1995-10-02
ZA914707B (en) 1993-02-24
IE912094A1 (en) 1992-01-01
ES2071919T3 (es) 1995-07-01
GB9013750D0 (en) 1990-08-08
CA2044748C (en) 1998-02-03
CN1057464A (zh) 1992-01-01

Similar Documents

Publication Publication Date Title
AU626757B2 (en) Pyrazolopyrimidinone antianginal agents
EG19978A (en) Process for preparing of pyrazolopyrimidinone antianginal agents
GB9213623D0 (en) Therapeutic agents